export default function Follistatin344OverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Follistatin-344 blocks myostatin &mdash; the protein that limits how much muscle your body will allow you to build. Transgenic mice and cattle with myostatin knocked out are dramatically more muscular, and those images are what drive the hype. The gap between those dramatic animal results and what injected follistatin peptide actually does in a human body is enormous and largely uncharacterized. The activin suppression that comes alongside myostatin blockade has documented connections to cancer progression that the bodybuilding community systematically underweights.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Muscle-Building Enthusiast &mdash; Wants to break through a plateau</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve seen the pictures of those myostatin knockout animals with ridiculous muscle mass. If follistatin blocks the same pathway, why isn&rsquo;t everyone using this?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The animal data is genuinely dramatic and the mechanism makes sense</strong><br />Myostatin is a protein your muscle cells produce that signals your body to limit muscle growth &mdash; an evolutionary brake that prevents metabolically expensive excessive muscle. Blocking it in animal models removes that brake entirely. The myostatin knockout mouse has roughly double the muscle mass of a normal mouse. That&rsquo;s a real biological fact, not marketing.</li>
          <li><strong>It seems like it should work the same way in humans</strong><br />The myostatin pathway is highly conserved across species. Rare humans with myostatin mutations are documented to have exceptional muscle mass with apparently normal health. The pathway exists the same way in human biology. The intuitive leap to &ldquo;blocking it should work in humans too&rdquo; is not unreasonable &mdash; it&rsquo;s just not established whether injected follistatin achieves the blockade required.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Follistatin-344 is a 344-amino-acid glycoprotein &mdash; a large, complex molecule that is genuinely difficult to manufacture correctly with intact structure and bioactivity. Whether research-grade products are actually correctly folded and active is unknown. Subcutaneous injection of large proteins faces serious degradation and bioavailability challenges that gene therapy (which delivered the protein directly into cells from a viral vector) does not. The activin suppression concern is not theoretical: follistatin also binds activin A, which has documented tumor-suppressive roles in several cancers. The bodybuilding community largely dismisses this because the desired effect looks so compelling. Have a current cancer screening before considering this and a hard stop if your history includes any relevant cancer. Net: dramatic animal data, unestablished human peptide pharmacology, and a non-trivial cancer concern that deserves honest consideration.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Competitive Athlete &mdash; Looking for every edge in muscle development</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I understand the evidence is thin, but I&rsquo;m already using research compounds and I want to think clearly about what follistatin-344 actually does and doesn&rsquo;t do before adding it to my stack.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re considering it</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The myostatin pathway is a genuine limit on muscle mass, not a myth</strong><br />Myostatin deficiency in humans and animals consistently produces supranormal muscle development with apparently maintained metabolic function. This isn&rsquo;t a pathway that &ldquo;might&rdquo; matter &mdash; it clearly does. If follistatin-344 injection could reliably block myostatin in muscle tissue with adequate pharmacokinetics, it would be relevant to anyone seriously pursuing maximal muscle development.</li>
          <li><strong>The pharmacokinetic question is the actual crux</strong><br />The relevant unknown for a thoughtful athlete is not whether myostatin matters &mdash; it does &mdash; but whether subcutaneous injection of this specific large protein achieves sufficient tissue concentrations to suppress myostatin signaling meaningfully and sustainably. Gene therapy bypasses this problem by producing follistatin locally. Peptide injection does not. This is the central empirical question that has no published human answer.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Activin A suppression will affect FSH secretion &mdash; activin stimulates FSH release from the pituitary. Long-term follistatin use in males would be expected to suppress FSH and likely reduce sperm production. In females it would be expected to disrupt the menstrual cycle. These are not minor considerations for athletes managing hormonal health alongside performance. The FSH suppression effect would be additive to any other hormonal compounds in a stack. The irreproducibility of the transgenic model effects through peptide injection is the core practical reality: the animal whose picture is driving the hype had its genome modified, not injected. Net: mechanistically sound interest in the pathway, but the pharmacokinetic bridge to benefit has not been established, and the hormonal side effects deserve weight.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Extreme Biohacker &mdash; Myostatin pathway, TGF-&beta; biology, pharmacokinetic reality</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to think through the follistatin pharmacology seriously &mdash; the TGF-&beta; ligand binding specificity, the FSH consequence of activin blockade, and why the pharmacokinetic gap between gene therapy models and peptide injection is so hard to bridge.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re interested</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The TGF-&beta; superfamily ligand binding profile is broader than the myostatin story implies</strong><br />Follistatin binds myostatin (GDF-8), activin A, activin B, GDF-11, and other TGF-&beta; superfamily members with varying affinity. The 344 splice variant has somewhat different binding than the 288 variant that is more predominant in some tissues. Activin A suppression in particular has documented roles in tumor suppression in endometrial, ovarian, prostate, and colorectal cancers &mdash; documented not as a theoretical risk but as characterized in peer-reviewed oncology literature. Follistatin overexpression is observed in cancer cells exploiting this to escape activin-mediated growth suppression.</li>
          <li><strong>The gene therapy to injection pharmacokinetic gap is mechanistically important and unresolved</strong><br />Primate gene therapy with AAV-follistatin produced significant muscle gains because the vector delivered the DNA payload directly into muscle cells, which then produced follistatin locally and continuously. Subcutaneous injection of the protein faces a fundamentally different challenge: the 344-amino-acid glycoprotein must survive enzymatic degradation at the injection site, be taken up by lymphatics, reach systemic circulation intact, and achieve muscle tissue concentrations sufficient to suppress myostatin signaling &mdash; while competing with endogenous follistatin-binding proteins. None of these pharmacokinetic steps have been characterized in humans for injected follistatin-344.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Product quality is a particularly serious concern for this specific compound. Follistatin-344 is a disulfide-bond-containing glycoprotein that requires correct folding to have biological activity. Most research peptide manufacturers are optimized for short synthetic peptides &mdash; not for correctly folding and glycosylating a 344-amino-acid protein. Community products may be misfolded, truncated, or biologically inactive while still testing as &ldquo;protein present.&rdquo; The risk of paying for inert material is higher than for nearly any other compound in this space. For someone serious about this area, bimagrumab (a clinical-stage anti-ActRIIB antibody with actual human RCT data in obesity and sarcopenia) represents a more tractable path to myostatin pathway intervention. Net: the biology is real, the pharmacokinetic bridge is unbuilt, the cancer risk is documented in the literature, and the product quality problem is more severe than for any other community muscle compound.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Follistatin-344 is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not proven to produce muscle gains via subcutaneous injection in humans &mdash; zero human peptide injection trial data exists</li>
              <li>Not the same intervention as the transgenic knockout animals whose images drive the community interest</li>
              <li>Not a myostatin-specific compound &mdash; it blocks activin A and other TGF-&beta; family members with documented cancer biology implications</li>
              <li>Not appropriate for anyone with cancer history or without recent cancer screening</li>
              <li>Not reliably bioactive from research-grade suppliers &mdash; correctly manufacturing a 344-AA glycoprotein is genuinely difficult</li>
              <li>Not hormone-neutral &mdash; activin suppression is expected to affect FSH and downstream reproductive hormone levels</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>The myostatin pathway is a real, conserved genetic limit on muscle growth &mdash; this is genuine biology, not marketing</li>
              <li>Animal and gene therapy data demonstrating the pathway&rsquo;s power is some of the most dramatic in all of muscle physiology research</li>
              <li>Rare humans with myostatin mutations demonstrate supranormal muscle mass &mdash; the pathway works the same way in human biology</li>
              <li>The TGF-&beta; superfamily biology is genuinely fascinating at a systems level &mdash; one ligand-trap protein regulating muscle growth, reproduction, inflammation, and tumor suppression simultaneously</li>
              <li>Understanding why gene therapy works and injected peptide probably doesn&rsquo;t is a valuable pharmacokinetics lesson for evaluating any large-protein research compound</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
